Famotidine

Introduction Overview

Generic Name

famotidine

Brand Name

Pepcid

Dosage Form

oral tablets, oral suspension, injectable form

Drug Class

H2 antagonists

Pharmacokinetics

Absorption: Famotidine is rapidly absorbed from the gastrointestinal tract with peak plasma concentrations typically reached within 1 to 3 hours after oral administration. The bioavailability of famotidine ranges approximately from 40% to 45%, and absorption is not significantly affected by food, allowing administration with or without meals. The onset of acid inhibition generally occurs within 15 minutes, with maximum suppression achieved within 1 to 3 hours, and the effect lasting up to 10 to 12 hours per dose.

Distribution: Famotidine distributes moderately throughout body tissues, with an approximate volume of distribution of 1.0 to 1.3 L/kg. The plasma protein binding of famotidine is low (about 15–20%), which facilitates efficient distribution to target tissues such as the gastric mucosa. The drug crosses the placenta and is found in small amounts in breast milk, necessitating caution during pregnancy and lactation.

Metabolism: Famotidine undergoes minimal hepatic metabolism. More than 65% of the administered dose is excreted unchanged via the kidneys. This limited metabolism reduces the risk of metabolic drug interactions. The low hepatic metabolism is clinically relevant, especially in patients with liver impairment as it requires little to no dose adjustment.

Elimination: The elimination half-life is approximately 2.5 to 4 hours in individuals with normal renal function. Famotidine is primarily eliminated by renal excretion through glomerular filtration and tubular secretion. In patients with renal impairment, famotidine clearance is significantly reduced, leading to prolonged half-life and necessitating dosage adjustments to avoid drug accumulation and toxicity. Less than 10% of the drug is metabolized, with the remainder excreted unchanged in urine, emphasizing the importance of renal function monitoring during therapy.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 10 mg, 20 mg, 40 mg
- Oral suspension (liquid): available as famotidine oral suspension for pediatric or patients unable to swallow tablets
- Injectable form: Famotidine for intravenous use
Dosages for Adults and Adolescents:
- For gastroesophageal reflux disease (GERD), duodenal ulcer treatment: 20 mg twice daily or 40 mg once daily at bedtime
- For prevention and treatment of active duodenal ulcers: 20 mg twice daily
- For Zollinger-Ellison syndrome or pathological hypersecretory conditions: initial dosage 20 mg every 6 to 12 hours, adjustable based on clinical response
- Over-the-counter (OTC) dosing for episodic heartburn: 10 mg or 20 mg once or twice daily (not to exceed 40 mg in 24 hours) for a maximum of 14 days
Specific Patient Populations:
- Renal impairment: Dose adjustment is necessary to reduce frequency or dosage according to the severity of renal dysfunction; for example, dosing interval extension or dose reduction to prevent accumulation due to decreased clearance
- Pediatric use: Oral suspension formulations are suitable for children, with dosing tailored by weight and indication
- Pregnant and breastfeeding patients: Use only if clearly needed and prescribed by a healthcare provider, as famotidine crosses placenta and is secreted in breast milk
Dosage Form Details:
- Oral tablets: solid, film-coated tablets available in 10 mg, 20 mg, and 40 mg strengths for ease of administration and dose flexibility
- Oral suspension: specially formulated liquid for accurate dosing in pediatric and special populations, measured with dosing syringe or device provided
- Injectable form: administered intravenously in hospital settings for severe acid-related conditions or when oral administration is not feasible

Mechanism Of Action

Famotidine is a selective histamine H2-receptor antagonist that competitively inhibits the action of histamine at H2 receptors located on the parietal cells of the stomach lining. By blocking these receptors, famotidine effectively suppresses the basal and stimulated secretion of gastric acid, including that induced by gastrin and acetylcholine.

At the cellular level, the blockade of H2 receptors inhibits adenylate cyclase activity via Gs protein coupling, resulting in decreased cyclic AMP levels. This leads to reduced activity of the proton pump H+/K+ ATPase in parietal cells, which is responsible for secreting hydrogen ions into the gastric lumen. Consequently, the acidic environment of the stomach is diminished.

Biochemically, this reduction of gastric acid secretion increases gastric pH, providing symptomatic relief in acid-related diseases and allowing healing of acid-induced mucosal injury such as gastric and duodenal ulcers. It also prevents reflux of acid into the esophagus, alleviating symptoms of gastroesophageal reflux disease (GERD).

Compared to proton pump inhibitors (PPIs), which irreversibly inhibit the H+/K+ ATPase pump, famotidine provides a reversible blockade, leading to a quicker onset of action but potentially less profound acid suppression. However, it has the advantage of fewer drug interactions and a more favorable safety profile in certain patient populations.

Clinical studies have demonstrated famotidine’s efficacy in reducing gastric acidity, healing ulcers, preventing their recurrence, and treating symptoms associated with hypersecretory conditions like Zollinger-Ellison syndrome. The drug’s ability to rapidly inhibit acid secretion makes it valuable in acute management and prophylaxis of acid-related gastrointestinal diseases.

Pharmacological Actions

Selective antagonism of histamine H2 receptors on gastric parietal cells
Reduction of basal and stimulated gastric acid secretion
Increase in gastric pH leading to reduced acidity
Inhibition of both daytime and nocturnal acid secretion
Promotion of healing in acid-related gastric and duodenal ulcers
Alleviation of symptoms associated with gastroesophageal reflux disease (GERD)
Reduction of gastric acidity in Zollinger-Ellison syndrome and other hypersecretory states
Minimal hepatic metabolism limiting potential for cytochrome P450 interactions
Rapid onset of action with acid inhibition within 15 to 60 minutes
Prolonged acid suppression lasting 10 to 12 hours per dose
Limited plasma protein binding enhancing tissue distribution
Favorable safety profile with low incidence of systemic side effects
Compatibility with antacids, allowing concomitant use for symptomatic relief
Reduced influence on gastric motility compared to some acid suppressants
Effective oral and parenteral routes allowing versatility in clinical use

Therapeutic Or Clinical Uses

Treatment and prevention of gastric and duodenal ulcers
Management of gastroesophageal reflux disease (GERD) and erosive esophagitis
Treatment of Zollinger-Ellison syndrome and other pathological gastric hypersecretory conditions
Reduction of acid reflux symptoms such as heartburn and acid indigestion
Prevention of ulcer recurrence in patients at risk
Adjunctive treatment in patients requiring nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce ulcer risk
Treatment of conditions involving excess stomach acid production
Short-term relief of episodic heartburn in adults and adolescents
Management of esophageal inflammation secondary to acid exposure
Reduction of stress-related mucosal bleeding in critically ill patients (parenteral use)
Therapy for gastritis associated with acid hypersecretion
Prophylactic use to prevent aspiration pneumonitis during anesthesia
Off-label use for symptoms of Zollinger-Ellison in combination with other therapies
Supportive care in patients with acid-related dyspepsia
Used in combination therapy with antimicrobials for Helicobacter pylori eradication regimens

Side Or Adverse Effects

Headache is a commonly reported mild adverse effect
Dizziness and light-headedness reported, especially in elderly or renal-impaired patients
Gastrointestinal disturbances including constipation or diarrhea
Confusion and agitation, particularly in older adults or those with renal impairment
Hallucinations and seizures in rare cases, requiring immediate medical attention
Unexplained muscle pain, tenderness, or weakness possibly indicating rhabdomyolysis
Allergic reactions such as urticaria, swelling of face, lips, tongue, or throat may occur
Rare reports of arrhythmia including fast or pounding heartbeat and potential QT prolongation
Fatigue and malaise occasionally reported
Transient elevation of liver enzymes in rare cases
Injection site reactions (for intravenous formulations) including pain or inflammation
Potential development of vitamin B12 deficiency with prolonged use due to decreased acid secretion
Overdose symptoms may include severe dizziness and cardiac disturbances
Potential mild respiratory symptoms such as cough or bronchospasm in sensitive individuals
Delayed hypersensitivity reactions including rash or fever are rare but possible

Precautions

Use cautiously in patients with renal impairment; dosage adjustment necessary
Monitor patients with liver disease although minimal hepatic metabolism occurs
Assess patients with history or family history of Long QT syndrome prior to therapy
Avoid use if known hypersensitivity to famotidine or other H2 antagonists like ranitidine, cimetidine, or nizatidine
Inform healthcare provider of history of stomach cancer before initiating therapy
Use under supervision during pregnancy and lactation to avoid potential fetal or neonatal exposure
Avoid excessive alcohol consumption which may exacerbate gastrointestinal side effects
Be vigilant for signs of serious allergic reactions and seek emergency care if they occur
Not recommended for heartburn symptoms lasting more than 14 days without medical evaluation
Do not exceed maximum recommended dosage to prevent toxicity
Use caution in elderly individuals who may be more susceptible to central nervous system effects
Avoid concomitant use of other acid-reducing agents unless directed by a healthcare provider
Monitor for signs of vitamin B12 deficiency with long-term treatment
Educate patients to recognize symptoms mimicking heart attack and seek immediate care if such symptoms arise
Use caution when co-administering with drugs affected by gastric pH alterations

Warnings

Do not use if allergic to famotidine or other H2 antagonists such as ranitidine, cimetidine, or nizatidine
Heartburn symptoms may mimic heart attack; seek emergency treatment if chest pain radiates or is associated with sweating and nausea
Potential for central nervous system side effects including confusion, agitation, hallucinations especially in elderly or renally impaired patients
Severe allergic reactions including anaphylaxis can occur; discontinue immediately if symptoms develop
Use caution in patients with asthma, chronic obstructive pulmonary disease (COPD), or other respiratory illnesses
Avoid use beyond 14 days for OTC indications without medical supervision
Risk of QT interval prolongation in susceptible individuals; avoid in patients with known Long QT syndrome
Not recommended for pediatric patients under 12 years without medical guidance
Pregnancy and breastfeeding use only if benefits outweigh risks; consult healthcare provider
Avoid abrupt discontinuation in severe acid hypersecretory states without medical advice
Alcohol intake may increase risk of gastric irritation when using famotidine
May mask symptoms of more serious underlying gastrointestinal disorders; medical evaluation advised if symptoms persist
Injection use reserved for hospital settings due to potential for injection site reactions and monitoring requirements
Do not share medication with others even if symptoms appear similar
Report any unusual changes in fatigue, muscle pain, urinary changes, or neurological symptoms promptly

Contraindication

Known hypersensitivity or allergy to famotidine
Allergy to other H2 receptor antagonists including ranitidine, cimetidine, or nizatidine
Patients with history of severe allergic reaction to Pepcid or its components
Use contraindicated in patients with documented Long QT syndrome due to risk of arrhythmia
Hypersensitivity to any inactive ingredient in the formulation, particularly in oral suspension or injectable preparations
Patients with acute porphyria (caution advised; consider alternative therapies)
Severe renal impairment patients refusing dose adjustment and monitoring
Use in neonates and infants under 1 month is generally contraindicated unless specifically directed
Contraindicated for extended OTC use beyond recommended duration without medical supervision
Concurrent use with drugs contraindicated with famotidine due to absorption interference unless specifically instructed
Individuals with galactose intolerance or sucrose deficiency should avoid certain oral suspension formulations
Contraindicated in patients with hypersensitivity to any component used in intravenous preparations
Patients with uninvestigated gastrointestinal bleeding until diagnosis established
Use contraindicated in cases where diagnostic masking of symptoms could delay appropriate treatment
Contraindicated for self-medication in patients with severe or persistent gastrointestinal symptoms

Drug Interactions

Famotidine reduces gastric acidity which may impair absorption of drugs requiring acidic pH, such as cefditoren
Decreased absorption of dasatinib when co-administered, potentially reducing therapeutic efficacy
Potential reduced bioavailability of delavirdine and other similar antiretroviral agents due to elevated gastric pH
Interaction with fosamprenavir may affect plasma concentrations and antiviral activity
Tizanidine plasma levels may increase when taken with famotidine liquid, raising risk of adverse effects
Concurrent use with other acid-reducing agents (e.g., proton pump inhibitors) may result in additive acid suppression
Concomitant use with antacids is generally safe, but spacing administration is advised to optimize efficacy
Potential interference with absorption of vitamin B12, ketoconazole, and iron preparations
Minimal cytochrome P450 mediated interactions due to low hepatic metabolism
No significant interaction with warfarin or antiplatelet agents, but clinical monitoring recommended
Possible reduced absorption of drugs requiring acidic environment such as itraconazole
Drug interactions with over-the-counter herbal supplements are not well studied; caution advised
Drugs requiring acid for solubility may have reduced effect when administered with famotidine
Monitor for therapeutic failure when initiating or discontinuing famotidine in patients on narrow therapeutic index drugs
Use caution when combining famotidine with other medications affecting heart rhythm due to additive QT prolongation risk

Preparations Of The Drug

Pepcid Tablets: film-coated oral tablets in 10 mg, 20 mg, and 40 mg strengths
Pepcid Oral Suspension: liquid formulation designed for pediatric use and patients unable to swallow tablets
Pepcid Injection: sterile injectable solution for intravenous administration in hospital settings
Pepcid Complete: an over-the-counter combination product containing famotidine together with an antacid for rapid and sustained relief
Acid Controller Original Strength and Maximum Strength: branded products including famotidine tablet formulations
Heartburn Relief Maximum Strength: combination products featuring famotidine for acid suppression plus antacids
Topcare Acid Reducer: generic or store-branded famotidine oral products
Berkeley and Jensen Acid Controller Maximum Strength: marketed preparations containing famotidine for heartburn
Oral dosing forms supplied with dosing syringe or measuring device for liquid preparations
Parenteral preparation supplied in vials for intravenous use, typically in doses of 20 mg/2 mL
Products available in both prescription and over-the-counter formats
Formulations designed to maintain stability at room temperature, with storage instructions to avoid moisture, heat, and freezing
Packaging includes instructions on measuring liquid dose accurately and disposal of unused liquid after 30 days
Various generic and branded forms meeting regulatory standards for quality and bioequivalence
Packaging designed for easy identification and to minimize medication errors